How Prelude Therapeutics is advancing a JAK2 JH2 strategy into the clinic after FDA IND clearance
FDA clears Prelude Therapeutics’ IND for PRT12396. Discover what this mutant-selective JAK2 approach could change for MPN drug development.
Pharma & Biotech